Trying to Diminish Cellulite? Here's How

Article

The new minimally invasive procedure, Cellfina System, was approved by the US Food and Drug Administration (FDA) to help clear the appearance of cellulite for at least a one-year period.

The new minimally invasive procedure, Cellfina System, was approved by the US Food and Drug Administration (FDA) to help clear the appearance of cellulite for at least a one-year period.

While existing cellulite reduction methods often include a combination of weight loss, laser or radiofrequency systems, or liposuction, the Cellfina System uses proprietary technology to target and treat the structural cause of cellulite.

The system works by releasing the fibrous bands just below the dimpled areas, resulting in a smoother appearance — potentially awarding patients with a higher level of confidence. Depending on the number of dimples being treated, the procedure takes less than an hour to complete.

Intended for long-term improvement in cellulite appearance specifically in the buttocks and thigh areas, the Cellfina System has not yet been tested for its safety and efficacy in other areas of the body. During testing, the most common adverse events reported were soreness, tenderness, and bruising.

Michael Kaminer, MD, dermatologist and managing partner at Skin Care Physicians and associate clinical professor of dermatology at Yale Medical School, said in a press release, “I’ve been practicing liposuction for 20 years, so I’ve been dealing with women and body issues and what they see when they look in the mirror for a long time. It’s a really neat thing to have the technology now that allows me to say, I can help you.”

Related Videos
Connective Tissue Disease Brings Dermatology & Rheumatology Together
What Makes JAK Inhibitors Safe in Dermatology
Potential JAK Inhibitor Combination Regimens in Dermatology
Therapies in Development for Hidradenitis Suppurativa
"Prednisone without Side Effects": The JAK Inhibitor Ceiling in Dermatology
Discussing Changes to Atopic Dermatitis Guidelines, with Robert Sidbury, MD, MPH
How Will Upadacitinib, Povorcitinib Benefit Hidradenitis Suppurativa?
The JAK Inhibitor Safety Conversation
Jonathan Silverberg, MD, PhD, MPH | Credit: George Washington University
Secukinumab and Bimekizumab for Hidradenitis Suppurativa
© 2024 MJH Life Sciences

All rights reserved.